Rubio Terrés C, López Alvarez M, Vargas Castrillón E
Subdirección General de Evaluación de Medicamentos, Ministerio de Sanidad y Consumo, Madrid.
Rev Clin Esp. 1990 Feb;186(2):84-7.
Almitrine dimesylate is a peripheral respiratory stimulant which is effective both on long and short term treatment of chronic obstructive lung disease. The individual therapeutic response, however, is very variable and approximately 25% of patients might not respond to treatment. The recommended doses are 50-100 mg per day during two months, followed by a resting month. Higher doses or longer treatments could provoke high serum levels which in turn would increase the risk of pulmonary hypertension and peripheral neuropathies. Almitrine is not commercialized in Spain as a single drug or for the cited indications.
二甲磺酸烯丙哌三嗪是一种外周呼吸兴奋剂,对慢性阻塞性肺疾病的长期和短期治疗均有效。然而,个体治疗反应差异很大,约25%的患者可能对治疗无反应。推荐剂量为每天50 - 100毫克,持续两个月,随后休息一个月。更高剂量或更长疗程可能导致血清水平升高,进而增加肺动脉高压和周围神经病变的风险。在西班牙,烯丙哌三嗪不作为单一药物或针对上述适应症上市。